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ABSTRACT

Amethod for treating ischemia by administering deltorphins
to a mammal. Deltorphin I SEQ ID NO:1, delntorphin II
SEQ ID NO:2 or combinations of deltorphins I SEQ ID
NO:1 and II SEQ ID NO:2 may be administered. A deltor

phin concentration of about 0.5—20 mg/kg body Weight, or
alternatively a loWer concentration of about 1—1000 tag/kg

body Weight of the mammal in a physiologically acceptable
formulation is administered up to four hours after an

ischemic episode. Deltorphins may also be administered
prior to or concurrently With onset of ischemia. Cerebral or
spinal cord ischemia or ischemic heart disease may be

treated using the method of the invention.

25 Claims, No Drawings
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METHOD FOR TREATING ISCHEMIA

alternatively loWer doses in the range of about 1 pig/kg body
Weight to about 1000 pig/kg body Weight of the mammal.

This application is a continuation of U. S. application
Ser. No. 09/302,820, ?led April 30, 1999 noW abondoned,
Which claims the bene?t of U. S. provisional application Ser.
No. 60/083,866, ?led May 1, 1998.

Preferably, the mammal is a human.
DETAILED DESCRIPTION

FIELD OF THE INVENTION
The invention relates to the use of deltorphins to treat

cerebral ischemia and ischemic heart disease.

10

BACKGROUND

With alanine as either the L- or D- isomer. Deltorphin II SEQ

ID NO:2 has the amino acid sequence Tyr-Ala-Phe-Glu-Val

Tissues deprived of blood and oxygen undergo ischemic
necrosis or infarction With possible irreversible organ dam
age. Cerebral ischemia results from decreased blood and

Val-Gly-NH2 With alanine as either the L- or D-isomer.
15

SEQ ID NO:2 may be used in the invention. Deltorphins
may be obtained from frog skin extracts or may be synthe
siZed using a commercial peptide synthesiZer such the type

the brain. In cerebral ischemia, the individual suffers a stroke

With sudden development of a focal neurologic de?cit and,
20

symptoms or both that can be referred to cervical, thoracic
or lumbar levels of the spine. Ischemic heart disease results
from an imbalance betWeen myocardial oxygen supply and
demand. In ischemic heart disease, the individual suffers

Deltorphins can be administered to ameliorate or inhibit

25

atherosclerotic obstruction of one or more large coronary

?oW, or may result from the rupture of a vessel in the
30

readily made by one of ordinary skill in the art. Signs of
35

a computed axial tomography (CT) scan of the brain.
If a stroke occurs, deltorphins can be administered to limit
40

consequence of inadequate cardiac perfusion pressure due to
hypotension from any cause.
Current treatments for ischemia encompass behavioral
45

50

SUMMARY OF THE INVENTION

The present invention ?lls this need by providing a
method of treating ischemia in a mammal comprised of
55

60

The present invention is also directed to a method of
treating cerebral or spinal cord ischemia or ischemic heart

mg/kg body Weight to about 20 mg/kg body Weight, or

Very often a stroke is caused by a cerebral embolism, the
likelihood of Which can frequently be predicted. In these
cases, the deltorphin can be administered prophylactically to
prevent or lessen the amount of brain tissue injured during
such an event. Many types of heart disease including cardiac
arrhythmias or diseases due to cardiac structural abnormali
ties may produce cerebral emboli. Atrial ?brillation from
any cause, including rheumatic valvular disease, may result
in emboli being produced Which can migrate into the arteries
of the brain. Emboli formation and migration can occur as
a result of arteriosclerotic cardiovascular disease and myo
cardial infarction. Emboli formation is also a de?nite risk for

bypass surgery and angioplasty can result in the formation of
microemboli Which can migrate into the arteries of the brain

administering a pharmaceutically effective amount of a

disease in a mammal comprised of administering a pharma
ceutically effective amount of a deltorphin to said mammal.
Preferably, the deltorphin is administered in a pharma
ceutical composition at a dosage in the range of about 0.5

direct injection into the brain, e.g, intracerebroventricular
injection for dispersion into other areas.

intracardiac surgery and prosthetic valve replacement. Heart

reducing the effect of an ischemic episode comprised of
deltorphin to said mammal.

injury to the brain. The ideal mode of administration is by
intraperitoneal (i.p.) or intravenous (iv) injection at a dose
of about 0.5—20 mg/kg, or alternatively of about 1—1000
pig/kg. Deltorphins can also be administered by subcutane
ous or intraarterial injection into the carotid artery, or by

are frequently preferred before resorting to invasive proce
dures and to provide more immediate relief than long-term
behavioral changes. Thus, there is a need for a therapeutic
agent Which can be useful in treating or preventing ischemia.

administering a pharmaceutically effective amount of a
deltorphin to said mammal. The ischemic tissue may be
brain, spinal cord or heart.
The present invention is also directed to a method of

impairment of gait, cortical sensory loss over toes, foot and
leg and urinary incontinence, to name just a feW. The

diagnosis can be con?rmed by cerebral angiography and by

carrying capacity of the blood such as in anemia, or as a

changes, drug therapy, and/or surgical intervention. Drugs

subarachnoid space or intracerebral tissue.
The main causes of ischemic stroke are thrombosis,
vasoconstriction and embolism. Diagnosis of a stroke can be

stroke include paralysis, slurred speech, general confusion,

aortitis, coronary artery spasm, congenital abnormalities of
the coronary circulation, increased myocardial oxygen
demands exceeding the normal supply capabilities as in
severe myocardial hypertrophy, reduction in the oxygen

may be intrinsic to the vessel itself such as in
arteriosclerosis, or may originate from a remote location
such as an embolus, or may result from decreased perfusion

or increased blood viscosity With inadequate cerebral blood

angina pectoris, acute myocardial infarction or sudden
death. The imbalance may be caused by, for example,
arteries, nonatheromatous coronary obstructive lesions such
as embolism, coronary ostial stenosis associated With luetic

available from Applied Biosystems.
damage caused by a stroke. A stroke is the acute neurologic
injury caused by one of several pathologic processes involv
ing the blood vessels of the brain. The pathologic process

atherosclerosis, trauma, aneurysm, developmental
malformation, altered permeability of the vessel Wall or
increased viscosity or other quality of the blood. Decreased
blood How may also be due to failure of the systemic
circulation and severe prolonged hypotension. Ischemic
necrosis of the spinal cord may result in sensory or motor

Either deltorphin I SEQ ID NO:1, deltorphin II SEQ ID
NO:2 or a combination of deltorphin I SEQ ID NO:1 and II

oxygen ?oW implicating one or more of the blood vessels of

in most cases, some degree of brain damage. The decreased
blood How may be due to, for example, an occlusion such as
a thrombus or embolus, vessel rupture, sudden fall in blood
pressure, change in the vessel lumen diameter due to

Deltorphins are endogenous linear heptapeptides isolated
from skin extracts of the South American frog Phyllomea'usa
bicolor. These may be further divided into deltorphin I SEQ
ID NO:1 and deltorphin II SEQ ID NO:2 depending on their
amino acid sequence. Deltorphin I SEQ ID NO:1 has the
amino acid sequence Tyr-Ala-Phe-Asp-Val-Val-Gly-NH2

and cause a series of occlusions in a number of arteries,

resulting in mental impairment. Cerebral embolism is also
the principal complication in the transplant of arti?cial
hearts. Furthermore, the overall risk of stroke after any type
of general surgery is 0.2 to 1 percent. The vegetations of
65

acute and subacute bacterial endocarditis can give rise to
emboli Which can occlude a major intracranial artery. Thus,
When these disease states or surgical procedures are planned
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or are happening, deltorphins can be administered to prevent

clinical evidence of myocardial ischemia; and those at high

brain damage due to any resultant emboli and stroke.

risk after myocardial infarction because of the recurrence of

Deltorphins can be administered to ameliorate or prevent

angina, heart failure, frequent ventricular premature

ischemic necrosis of the spinal cord. The ischemia may be
caused by an endarteritis of surface arteries leading to

contractions, or signs of ischemia in the stress test, to name

thrombosis. Atherosclerotic thrombosis of the aorta or dis

just a feW. Deltorphins may be administered either sepa
rately or in combination With other cardiac drugs such as

secting aortic aneurysms may cause infarction of the spinal

nitrates, beta-adrenergic blockers, calcium channel antago

cord (myelomalacia) by occluding nutrient arteries at

nists and/or aspirin and either separately or in combination
With ?brinolytic drugs such as tissue plasminogen activator
(tPA), streptokinase and urokinase. Use of deltorphins may

cervical, thoracic or lumbar levels, as can paralysis during
cardiac surgery requiring clamping of the aorta for more
than 30 minutes and aortic arteriography. Infarctive or

10

hemorrhagic vascular lesions of the spinal cord
(hematomyelia) may result in the sudden onset of symptoms
referable to sensory or motor or both spinal tract lesions.
Deltorphins can also be administered to ameliorate or

inhibit damage caused by ischemic heart disease. Ischemic

artery bypass grafting.
According to the present invention, deltorphins are
15

heart disease is a general term for a spectrum of diseases of

diverse etiology caused by an imbalance betWeen oxygen
supply and demand. The usual cause of the imbalance is
atherosclerotic obstruction of large coronary arteries, lead
ing to an absolute decrease in coronary artery blood ?oW. An
imbalance may also result from nonatheromatous coronary

dextran or dimethylsulfoxide to form a solution. The solu
20

A preferred deltorphin dose is in the range of about 0.5
25

is preferably up to about four hours after onset of an

ischemic episode. HoWever, the deltorphin may be admin
30

or as a consequence of inadequate perfusion pressure due to

35

of the heart. Such changes include inversion of the T Wave
40

50

lschemia Was induced by transient occlusion of the exter

nal carotid artery (ECA). Male ICR mice Weighing about
55

of ischemic heart disease to reduce or prevent disease
60

to the folloWing patients: those having careers that involve

are 45 or older and females Who are 55 or older Who Will

p02, pCO2 and pH.
A midline incision Was made in the skin of the neck and
the left common carotid artery (LCCA) Was exposed. The

the safety of others (e.g., commercial airline pilots) and that
present With questionable symptoms, suspicious or positive

undergo valve replacement and Who may or may not have

30—35 g Were anesthetiZed With an intraperitoneal (i.p.)

injection of chloral hydrate (350 mg/kg of body Weight) and
xylaZine (4 mg/kg of body Weight). Rectal temperatures
Were maintained at 37:0.5° C. With a heating pad and
incubator. The left femoral artery Was cannulated With a
PE-10 catheter for measurement of arterial blood pressure,

viduals having one or more risk factors and/or life style

noninvasive test results, and in Whom there are reasonable
doubts about the state of the coronary arteries; males Who

A murine model of ischemia/reperfusion injury Was used
to evaluate the effects of deltorphin on cerebral blood ?oW,
behavioral changes and ischemic infarct volume.
Induction of Ischemia

patterns, or to individuals already in the symptomatic phase

progression. Additionally, deltorphins may be administered

appreciated in light of the folloWing example.
EXAMPLE

recommended. In patients in the symptomatic phase of the

tension and certain personality traits.
Deltorphins may be administered to asymptomatic indi

behavioral tests such as cognitive recognition or memory
function such as the National Institutes of Health (NIH)
stroke scale.

cerebral infarct volume. This invention Will be further
45

until the extent of coronary artery blockage is Well
advanced, preventative measures to control risk factors and
life style patterns associated With the disease are also

family history of ischemic heart disease, diabetes,
hyperlipidemia, hypertension, obesity and cigarette smok
ing. Life patterns include sedentary lifestyle, psychosocial

noninvasive clinical imaging methods such as magnetic
resonance imaging (MRI) of the affected region to determine
the siZe of the damaged area. In cerebral ischemia, it is also
possible to assess neurologic de?cit by performance on

While the speci?c mechanism of deltorphin action on
ischemia is unknoWn, deltorphins exhibit a speci?c and
reproducible effect on decreasing neurological de?cit and

leading to ventricular tachycardia or ventricular ?brillation.
Stress tests and coronary arteriography may also provide
diagnostic information. These diagnostic test results may
determine the need for deltorphin administration.

disease, meticulous attention to life patterns or risk factors
must be given in an attempt to promote lesion regression or
at least prevent progression. Risk factors include a positive

istered concurrently With the onset of an ischemic episode or
even prior to onset of ischemia and still produce a thera

peutic effect.
Ef?cacy of deltorphin treatment may be evaluated using

be associated With angina pectoris; if prolonged, they can

Since ischemic heart disease is usually asymptomatic

mg/kg body Weight of the mammal to about 20 mg/kg body
Weight, or alternatively loWer doses of about 1 pig/kg body
Weight to about 1000 pig/kg body Weight of the mammal.
The time of administration of a single dose of the deltorphin

hypotension. When ischemic events are transient, they may

and displacement of the ST segment. Another important
consequence of myocardial ischemia is electrical instability

tion or emulsion may be administered by any route, but it is

preferably administered parenterally such as by intravenous,
intramuscular, intradermal or intraperitoneal injections.

of the blood such as in anemia or in the presence of

lead to myocardial necrosis and scarring With or Without the
clinical picture of acute myocardial infarction.
Ischemic heart disease may be readily diagnosed by one
skilled in the art. There may be predictive changes in the
electrocardiogram, since ischemia alters electrical properties

ischemia or ischemic heart disease. Deltorphins may be
formulated for administration in an aqueous based liquid
such as phosphate buffered saline to form an emulsion, or

demands exceeding the supply capabilities in a normal
coronary circulation, a diminished oxygen-carrying capacity

carboxyhemoglobin (e. g., due to cigarette or cigar smoking),

administered to a mammal to treat cerebral or spinal cord

they may be formulated in an organic liquid such as cyclo

obstructive lesions such as embolism, coronary ostial steno
sis associated With luetic aortitis, coronary artery spasm, or
very uncommonly an arteritis of the coronary vessels. The

imbalance may also be due to congenital abnormalities of
the coronary circulation, an increase in myocardial oxygen

prolong life and/or reduce or eliminate the need for invasive
procedures such as coronary arteriography and coronary

ECA, superior thyroid artery (STA) and occipital artery
(OA) Were isolated. The STA and OA Were electrocoagu
65

lated using a cautery probe (Baxter Hi Temp Cautery, Baxter
Healthcare Corp.) and divided. The base of the ECA Was
secured With a microsurgical clip, then the distal end of the

US 6,294,519 B1
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ECA Was ligated With a 6-0 nylon suture and the ECA Was
cut. A blunted 5-0 blue mono?lament nylon suture Was

(ANOVA) folloWed by the Bonferroni test. Statistical sig
ni?cance Was assigned to comparisons of sections from

placed in the end of the ECA, the surgical clip Was removed,

control versus DADLE- or deltorphin-treated animals With
p<0.05. Data Were expressed as meanistandard error of the

then the blunted suture Was advanced into the ECA until
resistance Was detected. The blunted suture Was then tight

mean (SEM).

ened to prevent both slipping of the internal suture and
bleeding. The suture Was trimmed and the incision Was

sealed by suturing the skin. The suture remained in place for
varying lengths of time up to 24 h. At the desired time,
reperfusion of the brain (restoration of blood How to the
brain) Was accomplished by retreating the suture from the

Results
Prior to DADLE treatment, there Were no signi?cant
10

ECA.

Mean arterial blood pressure (MABP), p02, pCO2 and pH
Were measured before occlusion, 10 min after occlusion and
30 min after reperfusion. Cerebral blood How Was monitored

15

2 mm posterior and 6 mm lateral to the bregma on the

ipsilaterial hemisphere of the brain.
20

Treatment

post ischemia. Ischemic volume Was measured and animals
Were assessed for behavior changes using a numerical

30

35

occlusion, both control and deltorphin-treated animals had a
25% reduction in cerebral blood ?oW Which Was sustained
for 1 h during the ischemia. After cessation of ischemia,
cerebral blood ?oW returned to baseline levels Within 0.5 h.
Post ischemia, there Were no signi?cant differences in
MABP, p02, pCO2, pH or rectal temperature betWeen con
trol animals and deltorphin-treated animals. There Was,

hoWever, a signi?cant (p<0.05) decrease in neurological
40

contralateral side (moderate); and 3=leaning to the contralat

45

animals (45:10 mm2) compared to control animals (73:13
mm2) after 24 h of reperfusion.
A method for treating cerebral or spinal cord ischemia or

eral side at rest or no spontaneous motor activity (severe).

ischemic heart disease by deltorphin administration is thus
disclosed. Deltorphins, either deltorphin I SEQ ID NO:1,

Evaluation of Treatment
Brain infarct volume Was measured after 1 h of ischemia

de?cits from deltorphin-treated animals (0.44:0.11) versus

control animals (1.55:0.19). Additionally, infarct volume
Was also signi?cantly reduced by 42% in deltorphin-treated

ranking from 0 to 3 according to the folloWing criteria: 0=no
observable de?cits (normal); 1 =failure to eXtend right

forepaW upon lifting by the tail (mild); 2 =circling to the

of reperfusion. HoWever, these differences in infarct volume
Were not statistically signi?cant.
Prior to deltorphin treatment, there Were no signi?cant

animals Were subjected to 1 h focal middle cerebral arterial

occlusion (MCAO) ischemia and 24 h of reperfusion. Cere
bral blood Was assessed by laser-Doppler ?oWmetry With a
?ber optic probe prior to ischemia and at 0.5 h, 1 h and 2 h

p02, pCO2, pH or rectal temperature betWeen control ani
mals and DADLE-treated animals. No changes occurred in
neurological de?cits betWeen control animals (1.75:0.18)
and DADLE-treated animals (1.73:0.20). Infarct volume
Was reduced by 12% in DADLE-treated animals (67:9

differences in MABP, p02, pCO2, pH or rectal temperature
betWeen control animals and deltorphin-treated animals.
Upon induction of ischemia by middle cerebral arterial

Control animals (n=8) received i.p. injections of saline or
1% cyclodeXtran. DADLE-treated animals (n=8) and
deltorphin-treated animals (n=8) received 4 mg/kg of either
DADLE or deltorphin at each of the folloWing times prior to
ischemic injury: 6.5 h, 4.5 h, 2.5 h and 0.5 h. At time 0,

during the ischemia. After cessation of ischemia, cerebral

mm2) compared to control animals (76:12 mm2) after 24 h
25

NO:1. For analysis of various test compounds, a solution of
the test compound in saline or 1 % cyclodeXtran Was
prepared. The test compound in solution Was administered
by ip injection at multiple doses prior to or up to 4 h

folloWing ischemic injury.

both control and DADLE-treated animals had a 20% reduc
tion in cerebral blood ?oW Which Was sustained for 1 h

blood ?oW returned to baseline levels Within 0.5 h. Post
ischemia, there Were no signi?cant differences in MABP,

by laser-Doppler ?oWmetry With a ?ber optic probe placed

Test compounds Were the delta opioid DADLE (Tyr-D
Ala-Gly-Phe-D-Leu-enkephalin) and deltorphin I SEQ ID

differences in MABP, p02, pCO2, pH or rectal temperature
betWeen control animals and DADLE-treated animals. Upon
induction of ischemia by middle cerebral arterial occlusion,

50

and again at 24 h after reperfusion. At the desired endpoint,

deltorphin II SEQ ID NO:2 or a combination of deltorphins
I SEQ ID NO:1 and II SEQ ID NO:2 are formulated for
biocompatable administration in a preferred dose in the

range of about 0.5—20 mg/kg, or alternatively 1—1000 pig/kg
body Weight of the animal. The deltorphin dose may be

the animal Was euthaniZed. The brain Was immediately

removed and placed into a mouse brain matriX (ASI, Warren,

MI) and 2 mm sections Were made. Brain sections Were 55 administered up to four hours after the onset of an ischemic

stained With 2% 2,3,5-triphenyltetraZolium chloride (TTC).

attack. Alternatively, the deltorphin dose may be adminis

Infarct siZe Was determined according to the formula:

tered prophylactically in patients at risk for an ischemic

attack such as, for example, prior to surgery. Deltorphin
administration reduces the effect of an ischemic event.

(contralateral volume-ipsilaterial undamaged volume)><100/con—
tralateral volume

60

to eliminate the effects of edema. Quantitation of contralat

eral and ipsilaterial volumes Was determined by image

analysis using a Scion Image (NIH Image Version 1.59)
modi?ed by Scion Corp. and Adobe Photoshop 2.0.1.
Statistical analysis of the volume analysis results Was
performed using the Student’s t-test or analysis of variance

It should be understood that the embodiments of the

present invention shoWn and described in the speci?cation

65

are only preferred embodiments of the inventors Who are
skilled in the art and thus are not limiting in any Way.
Therefore various changes, modi?cations or alterations to
these embodiments may be made or resorted to Without

departing from the spirit of the invention and the scope of
the folloWing claims.
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SEQUENCE LISTING

( 1) GENERAL INFORMATION:
(iii) NUMBER OF SEQUENCES: 2

(2)

INFORMATION FOR SEQ ID NO:

1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 :

Tyr Ala Phe Asp Val Val Gly
l

5

(2)

INFORMATION FOR SEQ ID NO: 2 :

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Tyr Ala Phe Glu Val Val Gly
l

5

35

ceutically effective concentration of a deltorphin selected

What is claimed is:
1. A method of treating ischemia in a mammal experi

from the group consisting of deltorphin I represented by
SEQ ID NO:1, deltorohin II represented by SEQ ID NO:2

encing ischemia comprising administering a deltorphin

and combinations thereof.
13. A method for reducing effects of an ischemic episode
in a mammal experiencing ischemia comprising administer
ing a pharmaceutically effective concentration of a deltor

selected from the group consisting of deltorphin I repre

sented by SEQ ID NO:1, deltorphin II represented by SEQ
ID NO:2 and combinations thereof to the mammal in a

parmaceutically acceptable formulation.
2. The method of claim 1 Wherein said
administered prior to onset of ischemia.
3. The method of claim 1 Wherein said
administered up to four hours subsequent
ischemia.
4. The method of claim 1 Wherein said

phin selected from the group consisting of deltorphin I

deltorphin is
deltorphin is
to onset of

represented by SEQ ID NO:1, deltorphin II represented by
45

episode.

deltorphin is
administered substantially concurrently With onset of

15. The method of claim 13 Wherein said deltorphin is
administered prior to said ischemic episode.
16. The method of claim 13 Wherein said deltorphin is
administered substantially concurrently With onset of

ischemia.
5. The method of claim 1 Wherein said deltorphin is
administered in the formulation selected from the group
consisting of a solution, an emulsion and a suspension.
6. The method of claim 1 Wherein said deltorphin is

ischemia.
17. A method of inhibiting ischemia in a mammal at risk

administered parenterally.
7. The method of claim 1 Wherein said deltorphin is
administered at a concentration in the range of about 0.5—20

55

tically acceptable formulation.

8. The method of claim 1 Wherein said deltorphin is

18. The method of claim 17 Wherein said deltorphin is
administered in the formulation selected from the group
consisting of a solution, an emulsion and a suspension.
19. The method of claim 17 Wherein said deltorphin is

administered at a concentration in the range of about 1—1000

pig/kg of body Weight of said mammal.
9. The method of claim 1 Wherein said deltorphin is
administered to treat cerebral ischemia.

administered parenterally.

10. The method of claim 1 Wherein said deltorphin is

20. The method of claim 17 Wherein said deltorphin is

administered to treat ischemic heart disease.

experiencing ischemia comprising administering a pharma

for ischemia comprising administering a deltorphin selected
from the group consisting of deltorphin I represented by
SEQ ID NO:1, deltorphin II represented by SEQ ID NO:2
and combinations thereof to the mammal in a pharmaceu

mg/kg of body Weight of said mammal.

11. The method of claim 1 Wherein said deltorphin is
administered to treat spinal cord ischemia.
12. A method for treating cerebral ischemia in a mammal

SEQ ID NO:2 and combinations thereof.
14. The method of claim 13 Wherein said deltorphin is
administered up to four hour subsequent to said ischemic

administered at a concentration in the range of about 0.5—20

mg/kg of body Weight of said mammal.
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21. The method of claim 17 Wherein said deltorphin is
administered at a concentration in the range of about 1—1000

pig/kg of body Weight of said mammal.
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22. The method of claim 17 wherein said deltorphin is
administered to prevent cerebral ischemia.
23. The method of claim 17 Wherein said deltorphin is
administered to prevent ischemic heart disease.
24. The method of claim 17 Wherein said deltorphin is
administered to prevent spinal cord ischemia.

effective concentration of a deltorphin selected from the

25. A method for inhibiting ischemia in a mammal at risk

for ischemia comprising administering a pharmaceutically

group consisting of deltorphin I represented by SEQ ID
NO:1, deltorphin II represented by SEQ ID NO:2 and
combinations thereof.
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